Bruchas Michael R, Toews Myron L, Bockman Charles S, Abel Peter W
Department of Pharmacology, Creighton University School of Medicine, 2500 California Plaza, Omaha, NE 68178, USA.
Eur J Pharmacol. 2008 Jan 14;578(2-3):349-58. doi: 10.1016/j.ejphar.2007.09.029. Epub 2007 Oct 2.
Alpha(1)-Adrenoceptors and extracellular signal-regulated kinases 1 and 2 (ERK1/2) regulate salivary secretion. However, whether alpha(1)-adrenoceptors couple to ERK1/2 activation and the specific alpha(1)-adrenoceptor subtypes involved in salivary glands is unknown. Western blotting of ERK1/2 phosphorylation showed phenylephrine activated ERK1/2 by 2-3-fold in submandibular gland slices and 3-4-fold in submandibular acinar (SMG-C10) cells with an EC(50) of 2.7+/-2 microM. ERK1/2 activation was blocked by either prazosin or HEAT, indicating alpha(1)-adrenoceptors stimulate ERK1/2 in native glands and SMG-C10 cells. Inhibition of [(125)I]HEAT binding by 5-methylurapidil (selective for alpha(1A) over alpha(1B/)alpha(1D)), but not BMY 7378 (selective for alpha(1D) over alpha(1A/)alpha(1B)), was biphasic and best-fit by a two-site binding model with K(i)(H) and K(i)(L) values for 5-methylurapidil of 0.64+/-0.3 and 91+/-7 nM, respectively, in SMG-C10 membranes. From these binding data, we obtained subtype-selective concentrations of 5-methylurapidil to determine the alpha(1)-adrenoceptor subtype/s activating ERK1/2 in SMG-C10 cells. 5-methylurapidil (20 nM) did not affect phenylephrine- or A-61603- (alpha(1A)-selective agonist) induced ERK1/2 activation; whereas, 30 microM chloroethylclonidine (alpha(1B)-selective antagonist) inhibited ERK1/2 activation by phenylephrine, indicating alpha(1B)-adrenoceptors, but not alpha(1A)-adrenoceptors, activate ERK1/2 in submandibular cells. We also examined alpha(1)-adrenoceptor location and dependence on cholesterol-rich microdomains for activating ERK1/2. Sucrose density gradient centrifugation showed 71+/-3% of alpha(1)-adrenoceptor binding sites were in plasma membranes. Cholesterol-disrupting agents filipin and methyl-beta-cyclodextrin inhibited phenylephrine-stimulated ERK1/2. These results show only alpha(1B)-adrenoceptors activate ERK1/2 and suggest subtype-specific ERK1/2 signaling by alpha(1B)-adrenoceptors may be determined by localization to cholesterol-rich microdomains in submandibular cells.
α1 -肾上腺素能受体与细胞外信号调节激酶1和2(ERK1/2)调节唾液分泌。然而,α1 -肾上腺素能受体是否与ERK1/2激活偶联以及唾液腺中涉及的特定α1 -肾上腺素能受体亚型尚不清楚。ERK1/2磷酸化的蛋白质印迹显示,去氧肾上腺素在颌下腺切片中使ERK1/2激活2 - 3倍,在颌下腺腺泡(SMG - C10)细胞中使ERK1/2激活3 - 4倍,半数有效浓度(EC50)为2.7±2微摩尔。哌唑嗪或HEAT均可阻断ERK1/2的激活,表明α1 -肾上腺素能受体在天然腺体和SMG - C10细胞中刺激ERK1/2。5 -甲基尿嘧啶(对α1A的选择性高于α1B/α1D)而非BMY 7378(对α1D的选择性高于α1A/α1B)对[125I]HEAT结合的抑制呈双相性,在SMG - C10细胞膜中,5 -甲基尿嘧啶的高亲和力解离常数(Ki(H))和低亲和力解离常数(Ki(L))值分别为0.64±0.3和91±7纳摩尔,由双位点结合模型最佳拟合。根据这些结合数据,我们获得了5 -甲基尿嘧啶的亚型选择性浓度,以确定在SMG - C10细胞中激活ERK1/2的α1 -肾上腺素能受体亚型。5 -甲基尿嘧啶(20纳摩尔)不影响去氧肾上腺素或A - 61603(α1A选择性激动剂)诱导的ERK1/2激活;而30微摩尔氯乙可乐定(α1B选择性拮抗剂)抑制去氧肾上腺素诱导的ERK1/2激活,表明在颌下腺细胞中是α1B -肾上腺素能受体而非α1A -肾上腺素能受体激活ERK1/2。我们还研究了α1 -肾上腺素能受体的定位以及激活ERK1/2对富含胆固醇微结构域的依赖性。蔗糖密度梯度离心显示71±3%的α1 -肾上腺素能受体结合位点位于质膜中。胆固醇破坏剂制霉菌素和甲基-β-环糊精抑制去氧肾上腺素刺激的ERK1/2。这些结果表明只有α1B -肾上腺素能受体激活ERK1/2,并提示α1B -肾上腺素能受体亚型特异性的ERK1/2信号传导可能由其定位于颌下腺细胞中富含胆固醇的微结构域所决定。